TL1A model of inflammation fibrosis and autoimmunity
This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.
1. An animal model for a disease and/or condition, comprising:
a transgenic rodent with a transgene overexpressing TL1A, wherein the TL1A overexpression is specific to an antigen presenting cell (APC) or dendritic cell (DC).
2. An animal model for a disease and/or condition, comprising:
a transgenic rodent with a transgene overexpressing TL1A, wherein the TL1A overexpression is specific to a T-cell.
3. The animal model of claim 1 , wherein the transgenic rodent has increased T-cell expression of one or more of the markers selected from the group consisting of CD4, CD8, CD86, CCR9, CCR10, FoxP3, TNF-α, IFN-γ, IL-10 and/or IL-17.
4. The animal model of claim 1 , wherein the antigen presenting cell (APC) or dendritic cell (DC) expresses a fluorescent marker.
5. The animal model of claim 1 , wherein the transgenic rodent expresses TL1A and GFP in about 35, 40, 45, 50, or 55% of all myeloid cells in a sample of myeloid cells isolated from the transgenic rodent.
6. An animal model for a disease and/or condition, comprising:
a transgenic rodent with a transgene overexpressing TL1A, wherein the TL1A overexpression is specific to a cell type, and wherein the transgenic rodent expresses TL1A and GFP in about 80, 85, 90, 95, or 99% of all T-cells in a sample of T-cells isolated from the transgenic rodent.
7. The animal model of claim 1 , wherein the transgenic rodent exhibits fibrostenosis, inflammation in the gastrointestinal (GI) tract, weight loss, and/or an increase in disease-activity index.
8. The animal model of claim 7 , wherein the fibrostenosis is induced using dextrose sodium sulfate (DSS).
9. The animal model of claim 1 , wherein the disease and/or condition is inflammatory bowel disease (IBD).
10. The animal model of claim 2 , wherein the transgenic rodent has increased T-cell expression of one or more of the markers selected from the group consisting of: CD4, CD8, CD86, CCR9, CCR10, FoxP3, TNF-α, IFN-γ, IL-10 and/or IL-17.
11. The animal model of claim 2 , wherein the T-cell expresses a fluorescent marker.
12. The animal model of claim 2 , wherein the transgenic rodent exhibits fibrostenosis, inflammation in the gastrointestinal (GI) tract, weight loss, and/or an increase in disease-activity index.
13. The animal model of claim 12 , wherein the fibrostenosis is induced using dextrose sodium sulfate (DSS).
14. The animal model of claim 2 , wherein the disease and/or condition is inflammatory bowel disease (IBD).
15. The animal model of claim 6 , wherein the transgenic rodent has increased T-cell expression of one or more of the markers selected from the group consisting of: CD4, CD8, CD86, CCR9, CCR10, FoxP3, TNF-α, IFN-γ, IL-10 and/or IL-17.
16. The animal model of claim 6 , wherein the transgenic rodent exhibits fibrostenosis, inflammation in the gastrointestinal (GI) tract, weight loss, and/or an increase in disease-activity index.
17. The animal model of claim 16 , wherein the fibrostenosis is induced using dextrose sodium sulfate (DSS).
18. The animal model of claim 6 , wherein the disease and/or condition is inflammatory bowel disease (IBD).